Grifols (GIKLY) Change in Working Capital (2010 - 2016)
Grifols (GIKLY) reported Change in Working Capital of $52.9 million for Q4 2016, up 138.84% on a YoY basis from $22.2 million in Q1 2016, and up 22.98% quarter-over-quarter from $43.0 million in Q3 2016.
Grifols (GIKLY) Change in Working Capital (2010 - 2016) Analysis & Trends
Grifols has reported Change in Working Capital for 6 years, with the latest figure at $52.9 million in Q4 2016.
- For the quarter ending Q4 2016, Change in Working Capital rose 138.84% year-over-year to $52.9 million; the trailing twelve-month figure through Dec 2016 stood at $46.9 million (down 46.73% YoY), and the FY2025 full-year result was $36.1 million, down 95.46% from the prior year.
- Change in Working Capital for Q4 2016 stood at $52.9 million, up from $43.0 million in the prior quarter.
- The five-year high for Change in Working Capital was $160.4 million in Q2 2012, with the low at -$136.3 million in Q4 2015.
- Historically, Change in Working Capital has averaged $56.6 million across 4 years, with a median of $78.0 million in 2012.
- Annual changes were most pronounced in 2012 — Change in Working Capital slumped 84.92% — and 2013, when it soared 109931.64%.
- Grifols' Change in Working Capital stood at $109.7 million in 2012, then slipped by 17.35% to $90.6 million in 2013, then slumped by 250.37% to -$136.3 million in 2015, then soared by 138.84% to $52.9 million in 2016.
- The last three Change in Working Capital figures came in at $52.9 million (Q4 2016), $43.0 million (Q3 2016), and -$136.3 million (Q4 2015), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Working Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 52.93 Mn |
| Dec 31, 2016 | 52.93 Mn |
| Sep 30, 2016 | 43.04 Mn |
| Sep 30, 2016 | 43.04 Mn |
| Dec 31, 2015 | -136.30 Mn |
| Dec 31, 2015 | -136.30 Mn |
| Sep 30, 2015 | 87.24 Mn |
| Sep 30, 2015 | 87.24 Mn |
| Jun 30, 2015 | 80.32 Mn |
| Jun 30, 2015 | 80.32 Mn |
| Mar 31, 2015 | 56.82 Mn |
| Mar 31, 2015 | 56.82 Mn |
| Mar 31, 2013 | 90.64 Mn |
| Mar 31, 2013 | 90.64 Mn |
| Dec 31, 2012 | 109.67 Mn |
| Dec 31, 2012 | 109.67 Mn |
| Sep 30, 2012 | 77.98 Mn |
| Sep 30, 2012 | 77.98 Mn |
| Jun 30, 2012 | 160.42 Mn |
| Jun 30, 2012 | 160.42 Mn |